AbbVie vs. Eli Lilly and: Which Healthcare Stock Is a Better Buy in 2026?
Yahoo Finance · Aug 29, 2026 · Apogee Therapeutics, Inc. Common Stock (APGE)
Eli Lilly's metabolic therapies drove 45% revenue growth, but its valuation premium demands scrutiny against AbbVie's defensive dividend appeal.
Not investment advice. Cached headline, not a full reprint.